A breakthrough in anti-infective therapy
Traditional anti-infective therapy relies on single, strong, immediate drug doses, triggering defensive dormancy among bacteria—making them harder to kill.
The founders of MiddleBrook™ Pharmaceuticals, Inc. recognized the limitations of modern anti-infective therapy and set out to approach the challenge differently. We began with a question.
Can a change in the dosing paradigm change the way bacteria respond to anti-infective therapy?
We discovered the answer is yes. In a break from traditional anti-infective therapy regimens, MiddleBrook exposed bacteria to rapid antibiotic pulses within the first hours of initial dosing. We found that pulsatile dosing appears to have the potential to cripple bacteria’s natural defense mechanisms and eliminate them more efficiently and effectively than traditional anti-infective therapy regimens.
The biological foundation of our approach
Our pulsatile dosing approach to anti-infective therapy has the potential to increase antibiotic efficacy by better addressing the growth cycles and natural defense mechanisms of bacteria. Studies show that antibiotics are most effective against actively growing bacteria. However, traditional anti-infective therapy methods, which focus on immediate-release doses, prompt bacteria to enter a dormant state, in which they may outlast the drug.
MiddleBrook’s preclinical studies show our staggered, gradually increasing dosing approach to anti-infective therapy may not effect the same defensive reaction. Bacteria may remain active, and can be eliminated more effectively—by the same amount of antibiotic.
With this proprietary knowledge in hand, MiddleBrook is endeavorily to redefine anti-infective therapy.
- Improved bactericidal activity
- Once-daily dosing
- Shorter duration of therapy
- Lower drug concentration
- Reduced side effects profile
- Decreased emergence of resistant bacteria
